Instrument Inactif

Autres langues TCR2 Therapeutics Inc.

Actions

TCRR

US87808K1060

Recherche biotechnologique et médicale

Autres langues

01/06/23	TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from NASDAQ Composite Index
01/06/23	TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from S&P Global BMI Index
01/06/23	TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from S&P TMI Index
01/06/23	Adaptimmune Therapeutics plc completed the acquisition of TCR2 Therapeutics Inc. from a group of shareholders.
24/05/23	TCR2 THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
23/05/23	TCR2 Therapeutics : Merger Agreement - Form 8-K
12/05/23	TCR-2 THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
11/05/23	TCR2 Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
11/05/23	TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
08/05/23	TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/05/23	TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26/04/23	TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
04/04/23	TCR-2 THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
03/04/23	TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/04/23	TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23/03/23	TCR2 THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
23/03/23	TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
23/03/23	TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
10/03/23	TCR2 THERAPEUTICS INC. : Regulation FD Disclosure (form 8-K)
10/03/23	Moore Kuehn Encourages KBAL, DSEY, RADI, and TCRR Investors to Contact Law Firm
09/03/23	TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
06/03/23	Sector Update: Health Care Stocks Hit by Late Selling
06/03/23	Top Midday Decliners
06/03/23	Top Midday Gainers
06/03/23	TCR2 THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)